AAO

The 29th Windoor Façade Expo Open Its Doors in Guangzhou

Retrieved on: 
суббота, апреля 8, 2023
Construction, Polaris, AAO, GRC, Bavarian Film Awards (Production Design), Adhesive, Perforation, Carbon, Ventilation, GRP, PUR, LED, UHPC, Forward Together PAC, BIPV, Hardware, Architecture, Urban renewal, Award, Polaris Award, Video game, Printed circuit board, Plaster

GUANGZHOU, China, April 7, 2023 /PRNewswire/ -- Held in Guangzhou on April 7-9, 2023, the 29th Windoor Façade Expo bring together more than 700 exhibitors and brands covering 100,000 square meters of exhibition space and gather an expected 100,000 visitors.

Key Points: 
  • GUANGZHOU, China, April 7, 2023 /PRNewswire/ -- Held in Guangzhou on April 7-9, 2023, the 29th Windoor Façade Expo bring together more than 700 exhibitors and brands covering 100,000 square meters of exhibition space and gather an expected 100,000 visitors.
  • Over 1,000 kinds of new designs, new technologies, new products and new materials of the entire supply chain of window, door and façade.
  • 8 Sectors Showcase Innovative Products of Window, Door and Façade Industry
    1.
  • The industry experts select 47 award-winning products out of 279 entries in 2023, which is the center stage at Windoor Façade Expo.

KronosMD Inc’s CEO Files Provisional Patent Application for an Advanced Ultrasound Dental Digital Impression System

Retrieved on: 
четверг, марта 23, 2023
Dental arch, Jaw, Dentistry, Meta-analysis, Intellectual property, AAO, Life, ESPE, IP, USD, Invention, Live Home 3D, Science, Direct, Home, Patent, United States Patent Office fire, OTC, KNOS, Consumer, World Intellectual Property Organization, Align Technology, Diagnosis, WIPO, Dental, Software, 3D printing, Medical imaging, Orthodontics

KronosMD believes this technology is the first of its kind and will improve the digital workflow of clear orthodontic aligner manufacturing.

Key Points: 
  • KronosMD believes this technology is the first of its kind and will improve the digital workflow of clear orthodontic aligner manufacturing.
  • The filing of this provisional patent application directly relates to KronosMD's intellectual property development goals to manufacture and market an advanced and innovative dental ultrasound imaging product line.
  • If approved, KronosMD believes this patent could significantly enhance manufacturing processes and workflows for the multi-billion clear orthodontic aligners market.
  • The issued patents and the provisional patents are in two main fields, remote at-home digital virtual imaging devices, and office-based dental ultrasound imaging platforms and sensors, covering KronosMD disruptive 3D medical ultrasound products and software.

MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results

Retrieved on: 
вторник, марта 14, 2023
ALS, Johnson & Johnson, DNA, Janssen Pharmaceuticals, Annual general meeting, Riboswitch, Eye, Abstract, Cell, Depreciation, Congress, PRO, AAV, Quality control, GMP, Gene, Patient, Insurance, Parkinson's disease, Research, Central nervous system, STN, European Society of Gene and Cell Therapy, S&P Global Ratings, CGMP, Safety, ESGCT, GAD, IND, Xerostomia, Treatment, BLA, AAO, Pharmaceutical industry, Sewage treatment, Birth control, Silviculture, Vaccine, Cryptocurrency, Janssen

LONDON and NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial and operational results for the fourth quarter and full-year ended December 31, 2022, and provided a corporate update.

Key Points: 
  • LONDON and NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial and operational results for the fourth quarter and full-year ended December 31, 2022, and provided a corporate update.
  • This progress across multiple programs and platforms is enabled by our broad end-to-end capabilities in vectorology optimization and manufacturing.
  • AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia:
    MeiraGTx reported positive clinical data from the AQUAx Phase 1 clinical trial in December 2022.
  • Research and development expenses for the years ended December 31, 2022, and 2021 were as follows (in millions):

Game Changing Dental Pain Eraser Recognized with Top Industry Innovation Award

Retrieved on: 
вторник, марта 14, 2023
Research, Tooth, Gel, Mouth, Committee, Food and Drug Administration, Aphthous stomatitis, Organization, American Association of Orthodontists, TMD, Pain, Brace, Food, Toothache, News, AAO, Dentistry, Orthodontics

This week, Dr. Cosmo Haralambidis of Synapse Dental LLC was recognized with the 2023 Ortho Innovator Award by the American Association of Orthodontists (AAO) Committee on Technology for inventing the Dental Pain Eraser, the world’s first pen-shaped, portable electronic dental anesthesia solution.

Key Points: 
  • This week, Dr. Cosmo Haralambidis of Synapse Dental LLC was recognized with the 2023 Ortho Innovator Award by the American Association of Orthodontists (AAO) Committee on Technology for inventing the Dental Pain Eraser, the world’s first pen-shaped, portable electronic dental anesthesia solution.
  • Through its Advanced PulseWave™ technology, the Dental Pain Eraser sends subsensory electric pulses to calm the nerves in the mouth and provide long-lasting pain relief.
  • “The Dental Pain Eraser is clinically proven to prevent and relieve oral pain in seconds and last for hours – reducing the need for local anesthetic injections, gels or drugs,” explains Dr. Cosmo.
  • In addition to the 2023 Ortho Innovator Award, the Dental Pain Eraser has been recognized by several industry leading organizations in recent months:
    The Dental Pain Eraser is cleared by the Food and Drug Administration for use with children and adults.

RD Fund Appoints Mark S. Blumenkranz, MD, MMS to Board of Directors

Retrieved on: 
вторник, февраля 28, 2023
AJO, AAO, Stanford University, Blumenkrantz, Doctor of Philosophy, Pharmacology, Research, MMS, Retina, Visual impairment, Growth, Management, MD, Ophthalmology

RALEIGH, N.C., Feb. 28, 2023 /PRNewswire/ -- Today, the RD Fund (Retinal Degeneration Fund), the venture arm of the Foundation Fighting Blindness, aimed at rapidly driving research toward preventions, treatments, and cures for retinal degenerative diseases, is proud to announce the appointment of Mark S. Blumenkranz, MD, MMS, to the RD Fund Board of Directors. Founding Board Member, Eugene de Juan, MD, has cycled off the RD Fund Board following four years of service.

Key Points: 
  • RALEIGH, N.C., Feb. 28, 2023 /PRNewswire/ -- Today, the RD Fund (Retinal Degeneration Fund), the venture arm of the Foundation Fighting Blindness, aimed at rapidly driving research toward preventions, treatments, and cures for retinal degenerative diseases, is proud to announce the appointment of Mark S. Blumenkranz, MD, MMS, to the RD Fund Board of Directors.
  • Founding Board Member, Eugene de Juan, MD, has cycled off the RD Fund Board following four years of service.
  • "Dr. Blumenkranz is an academic, clinical, and entrepreneurial leader in the field of retinal disease," said Adrienne Graves, PhD, Chair, RD Fund.
  • "I am honored to accept the role of board member with the RD Fund, an organization whose work cannot be overstated," said Mark S. Blumenkranz, MD, MMS.

Clinical trials results demonstrate value of home OCT at international meetings

Retrieved on: 
среда, февраля 22, 2023
AAO, Administration, Retina, Doctor of Philosophy, Angiogenesis, NOA, University, Alarm monitoring center, BIRAX, FDA, St Mary's University College, Belfast, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IRB, AMD, Medicare, Inc., Health, Degeneracy, American Academy of Ophthalmology, Tel Aviv Sourasky Medical Center, OCT, Food, Physician, American Academy, Medical imaging, Medical device, MD, Ophthalmology

A presentation by Nancy Holekamp, MD, Pepose Vision Institute, reviewed several clinical trials that show the progress toward implementing home OCT in the management of patients with wet AMD.

Key Points: 
  • A presentation by Nancy Holekamp, MD, Pepose Vision Institute, reviewed several clinical trials that show the progress toward implementing home OCT in the management of patients with wet AMD.
  • “The experience with home OCT has given me an understanding of the value of missing information in between the office visits,” Dr. Holekamp said.
  • Home OCT has received a “Breakthrough Device” designation by the U.S. Food and Drug Administration (FDA).
  • “The studies presented at the Angiogenesis and Macula Society meetings show critical milestones in bringing home OCT to market and expanding our digital health offerings in ophthalmology,” said Kester Nahen, PhD, CEO of Notal Vision.

Akari Therapeutics Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy (GA)

Retrieved on: 
среда, февраля 15, 2023
Choroid, CNV, LTB4, Vance DeGeneres, Eye, Engineering, Drug discovery, Professor, ARVO, Intravitreal injection, Anxiety, VEGF, VEGF-A, C5, E pluribus unum, Tufts University School of Medicine, Leukotriene B4, Depression, Food, Risk, Choroidal neovascularization, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Endothelium, GMP, Leukotriene, Hot game, Geographic atrophy, American Society for Clinical Investigation, Blood, Therapy, Andrew Conway Ivy, Patient, Incidence, Retina, IVT, Visual system, AAO, Intellectual property, Kinetics, AMD, Inflammation, Medscape, PAS, PEGylation, Injection, McClard, Infection, IND, Pharmaceutical industry, Vaccine, Ophthalmology, Medicare, Akari

PASylation (PAS) technology is a biological alternative to the chemical conjugate polyethylene glycol (PEGylation) in the development of extended half-life recombinant protein therapeutics.

Key Points: 
  • PASylation (PAS) technology is a biological alternative to the chemical conjugate polyethylene glycol (PEGylation) in the development of extended half-life recombinant protein therapeutics.
  • Complement overactivation is a validated target and an important aspect in the pathophysiology of GA, while LTB4 may contribute to overexpression of VEGF-A, a key driver of CNV.
  • “Patients who have geographic atrophy also are at risk of developing an additional sight-threatening condition known as choroidal neovascularization or CNV, which presents more hurdles in the fight to preserve sight.
  • Medscape article on 24-month data presentation at AAO 2022 With Approval Pending, Pegcetacoplan Shows Mixed Results for Treating Geographic Atrophy https://www.medscape.com/viewarticle/981813#vp_2
    McClard CK, et al.

Global Ocular Adhesives and Sealants Market Report to 2030 - Featuring Reliance Life-Sciences, Ocular Therapeutix, Baxter, Medtronic and Reliance Life-Sciences - ResearchAndMarkets.com

Retrieved on: 
среда, января 25, 2023
Chemicals, Plastics, Manufacturing, American Academy of Ophthalmology, Infection, Hospital, Korea Disease Control and Prevention Agency, Injury, Diagnosis, Occupational safety and health, Astigmatism, Suture, Endophthalmitis, National Institute for Occupational Safety and Health, CDC, NIOSH, Fibrin, American Academy, Prevalence, AAO, Adhesive, Medical device, Telescopic sight, Health

The demand for better surgical treatment is increasing, which is helping the market for ocular sealants grow.

Key Points: 
  • The demand for better surgical treatment is increasing, which is helping the market for ocular sealants grow.
  • Approximately 2,000 American workers suffer work-related eye injuries each day, according to the National Institute for Occupational Safety and Health (NIOSH).
  • These ocular sealants are used during wound reconstruction to improve the patient's post-operative state while preserving the wound's integrity.
  • Ocular sealants and adhesives are employed in a variety of indications because each type has distinct advantages and disadvantages.

Global Anodic Aluminium Oxide Wafer Market Report 2022: Increased Usage Of AAO Template For Making MEMs Devices Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
вторник, января 24, 2023
Pharmaceutical, Other Manufacturing, Health, Medical Devices, Consumer Electronics, Technology, Semiconductor, Manufacturing, Mannitol, Memory, Glycine, Electronics, Radio, RFIC, Gelatin, Growth, Microelectromechanical systems, AAO, Personal computer, HPC, Aluminium

The Global Anodic Aluminium Oxide Wafer Market size is expected to reach $254.8 Million by 2028, rising at a market growth of 21.0% CAGR during the forecast period.

Key Points: 
  • The Global Anodic Aluminium Oxide Wafer Market size is expected to reach $254.8 Million by 2028, rising at a market growth of 21.0% CAGR during the forecast period.
  • The ability of AAO template to help manufacture MEMs devices will boost the anodic aluminum oxide wafer market.
  • On the basis of wafer type, the anodic aluminum oxide wafer market is divided into 6-inch, 8-inch, 12-inch and others.
  • The pharmaceutical segment recorded a remarkable growth rate in the anodic aluminum oxide wafer market in 2021.

The Worldwide Ocular Adhesives and Sealants Industry is Expected to Reach $319.9 Million by 2030

Retrieved on: 
четверг, января 26, 2023
USD, Astigmatism, Tissue engineering, Endophthalmitis, Adhesive, American Academy of Ophthalmology, Infection, Diagnosis, CDC, NIOSH, Hospital, Korea Disease Control and Prevention Agency, Fibrin, Synthetic, American Academy, National Institute for Occupational Safety and Health, Prevalence, Occupational safety and health, AAO, Suture, Injury, Speciality chemicals, Medical device, Telescopic sight, Health

The global ocular adhesives and sealants market size is expected to reach USD 319.9 million by 2030, expanding at a CAGR of 8.28% from 2022 to 2030, according to this report.

Key Points: 
  • The global ocular adhesives and sealants market size is expected to reach USD 319.9 million by 2030, expanding at a CAGR of 8.28% from 2022 to 2030, according to this report.
  • The demand for better surgical treatment is increasing, which is helping the market for ocular sealants grow.
  • These ocular sealants are used during wound reconstruction to improve the patient's post-operative state while preserving the wound's integrity.
  • Ocular sealants and adhesives are employed in a variety of indications because each type has distinct advantages and disadvantages.